Neuroscientists identify a CRF-neuron "switch" in the brain's BNST region that, when activated, allows for significantly faster unlearning of fear responses.

Luvesilocin is a subcutaneously-administered, proprietary prodrug of the psilocybin-like compound 4-OH-DiPT designed to target the serotonin 2A receptor.

The presentation by Dr. Dirk Beher, Chief Executive Officer of FundaMental Pharma, will highlight the scientific foundation for lead candidate FMP374, the distinctive approach to modulating NMDAR, and ...

For millions of Americans struggling with depression, treatment will soon extend beyond clinics and pharmacies U.S. regulators have approved the first at-home brain stimulation device designed to ...

New research explores the risks and benefits of SSRI use during pregnancy, highlighting a link to gestational diabetes and ...

New study involving 50,000 children finds that those who spend over four hours a day on screens face up to 61% higher risk of depression.

After developing an AI tool that recommends antidepressants based on medical history, George Mason University researchers are now examining whether additional patient demographics, such as race and ...

Soumerai is a professor of population medicine at Harvard Medical School. Lu is a professor at the Sydney Pharmacy School of the University of Sydney. While his war on vaccines may be getting more ...

The U.S. Food and Drug Administration has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to typical antidepressants that can cause side ...

Flow's FL-100 device is expected to be available in the US as soon as Q2 2026. Image credit: Tada Images via Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Flow Neuroscience’s ...